Still guess work why she abstained but in the end funding will come when compelling data are presented with passion, with substance and an outlook for a high ROI no investor or pharma can refuse.
CHM's new CEO got the knowledge, the contacts, the passion and determination and can back it up with data for their 2 blood cancer allogeneic NK-cell CAR-Ts. Unfortunately they are in competition with almost 300 companies in that area and only the outlook for being the first or among the first to get approval will help them. And that's IMU's problem with Azer-Cell, it is allogeneic, got great ph1 data but apparently that is not enough to open the accounts or getting deals done. That way, not outstanding, or, not yet.
CHM's other 2 are autologous CAR-Ts, great underlying technologies but are too complex to get it done in non-specialised hospitals. They still rely on City of Hope, MD Anderson Texas and University Pennsylvania and Case Western. They now try at Peter Mac but all that effort not enough to attract funds.
LC might be a top leader in the clinical area but as we've seen so many times at her presentations, she is no sales woman. After any presentation the audience should be excited, having the feeling to miss out on the greatest opportunity ever. When she finishes, people seem to be tired, bored and clueless. No wonder the sp is at 4c.
The RAD CEO backed up by Lantheus / Lantheus "puppet" is now in charge and the new CEO at CHM step by step is taking on more responsibilities. There has been a fresh new start, something that is missing at IMU imo.
LC and PH are worn out, younger and fresher women / men power is needed to turn IMU away from a Titanic to a Space X - event.
I have sold my core a while ago and just trade the hell out of heads and OEs, hence the non-holder status. If there is a clear indication of an upwards trend I might reinvest in a core holding. Until then, the $$$$ are invested in comps close to CF+ but still ignored by the market.
Expand
(20min delay)